Comparison · NCT01559012-83caed9d
Clonidine vs Placebo: Number of Patients Choosing Active Treatment for Off-label, Compassionate Use.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Clonidine vs Placebo: Number of Patients Choosing Active Treatment for Off-label, Compassionate Use. Trial comparisons, record NCT01559012-83caed9d. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01559012-83caed9d
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.75 | 0.468 | 0.911 | wilson | |
| Risk in group 2 | 0.25 | 0.0889 | 0.532 | wilson | |
| Risk difference, group 1 minus group 2 | 0.5 | 0.101 | 0.728 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 3 | 1.07 | 8.43 | log | |
| Odds ratio, group 1 over group 2 | 9 | 1.42 | 57.1 | log | |
| Number needed to treat, for one more participant with the outcome on Clonidine than on Placebo | 2 | 1.37 | 9.92 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Clonidine | All patients were treated with TD clonidine for 5 days and switched to placebo for 5 days, or the other way round | 9 | 12 | OG000 |
| Group 2 | Placebo | All patients were treated with TD clonidine for 5 days and switched to placebo for 5 days, or the other way round | 3 | 12 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Patients Choosing Active Treatment for Off-label, Compassionate Use.
- Description
- the patients were asked to choose between two transdermal systems (active drug versus placebo) as the most effective
- Time frame
- at 10 days since start of treatment
- Population
- no determination of sample size
Source ClinicalTrials.gov
Trial
- Title
- Transdermal Clonidine in the Treatment of Severe Hyperemesis Gravidarum
- NCT number
- NCT01559012
- Phases
- PHASE3
- Conditions
- Hyperemesis Gravidarum
- Interventions
- Clonidine
- Lead sponsor
- A.O.U. Città della Salute e della Scienza
- Results first posted
- 2014-04-30
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01559012?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01559012-83caed9d